For the pharmaceutical industry, repurposing human medications for the veterinary market represents a highly lucrative economic opportunity. Developing a new drug from scratch is a billion dollar endeavor, but adapting an existing, FDA approved human drug for pets can bypass years of preliminary research.
A prime candidate for this strategy is a class of medications called SGLT2 inhibitors, specifically a drug named empagliflozin. Originally developed for human Type 2 diabetes, these drugs recently proved to be massive breakthroughs in human cardiology, reducing the risk of heart failure hospitalizations and cardiac death by up to 40%.
Naturally, veterinary researchers have been eager to see if this blockbuster drug could help dogs suffering from Dilated Cardiomyopathy (DCM). DCM is the second most common heart disease in dogs, characterized by an enlarged, weak heart that struggles to pump blood, ultimately leading to congestive heart failure and a poor prognosis.
The Mechanism: How SGLT2 Inhibitors Work
To understand the study, it helps to understand the drug's mechanism. SGLT2 (sodium glucose cotransporter 2) is a protein found in the kidneys that acts like a sponge, reabsorbing sugar from urine back into the bloodstream.
The Inhibitor: Empagliflozin blocks this protein, forcing the body to excrete excess sugar through the urine instead.
The Heart Benefit: By flushing out this sugar and associated fluids, the drug lowers blood volume and forces the heart to shift to a more efficient energy source (ketones), which significantly relieves stress on a failing human heart.
The Canine Clinical Trial
A 2025 master's thesis by researcher Andrea Plá at the University of Prince Edward Island put empagliflozin to the test in dogs. The investigation was split into two phases:
Phase 1: Six healthy dogs were given a single oral dose to ensure the drug was absorbed and biologically active.
Phase 2: Eight dogs diagnosed with DCM participated in a 30-day double blind, placebo-controlled trial, receiving a daily dose of 0.3 mg/kg.
The Results: Biological Success, Clinical Stagnation
From a purely biological standpoint, the drug did what it was designed to do. Dogs in both the healthy group and the DCM group experienced significant increases in urinary glucose, proving that the drug successfully inhibited the SGLT2 protein in the canine body.
However, the cardiovascular results were disappointing. After 30 days of treatment, the dogs with DCM showed no significant improvements in echocardiographic parameters (ultrasound measurements of heart size and pumping ability). Furthermore, there were no significant positive changes in cardiac biomarkers (blood tests that indicate heart muscle damage or stretch).
The Catch: An Unintended Side Effect
The most crucial takeaway for drug manufacturers lies in the side effects observed during the trial. Three dogs (one healthy, two with DCM) developed diarrhea after taking empagliflozin. One DCM patient's owner had to withdraw their dog from the study entirely due to persistent gastrointestinal distress.
The researcher theorizes that this side effect occurs because empagliflozin may not be as "selective" in dogs as it is in humans.
In humans, the drug almost exclusively targets SGLT2 in the kidneys.
However, the canine body also utilizes a very similar protein called SGLT1, which is located primarily in the small intestine.
If the drug accidentally blocks SGLT1 in dogs, it traps sugars inside the intestine, which draws in water and causes severe "osmotic diarrhea".
Industrial and Economic Implications
For veterinary pharmaceutical companies, these findings present a vital lesson. The direct translation of human SGLT2 inhibitors to the canine market will likely face substantial commercial hurdles if the gastrointestinal side effects prove common. Pet owners are highly sensitive to medications that negatively impact their dog's daily quality of life, and chronic diarrhea is a major barrier to market adoption.
To tap into the canine heart failure market (a significant economic sector given the high prevalence of DCM in large breeds) manufacturers may need to invest in dedicated veterinary R&D. Developing a novel SGLT2 inhibitor that is strictly tailored to avoid canine SGLT1 receptors will be necessary to safely unlock the cardioprotective benefits seen in humans.